Evidence map›Paper›PMID 29360990›Full record

ArticleThe Journal of antimicrobial chemotherapy2018

PBP4 activity and its overexpression are necessary for PBP4-mediated high-level β-lactam resistance.

Li Basuino, Ambre Jousselin, J Andrew N Alexander, Natalie C J Strynadka, Mariana G Pinho, Henry F Chambers, Som S Chatterjee

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Ftsh Sensitizes Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2021
    Article
  11. Article
  12. Review
  13. Article
  14. Constructing and deconstructing the bacterial cell wall.Protein science : a publication of the Protein Society · 2020
    Review
  15. Article
  16. Article
  17. PBP4: A New Perspective onMicroorganisms · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Li BasuinoDivision of HIV/AIDS, Infectious Diseases and Global Health, Department of Medicine, University of California, San Francisco, CA, USA.
Ambre JousselinInstituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.
J Andrew N AlexanderDepartment of Biochemistry and Molecular Biology and the Center for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
Natalie C J StrynadkaDepartment of Biochemistry and Molecular Biology and the Center for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
Mariana G PinhoInstituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.
Henry F ChambersDivision of HIV/AIDS, Infectious Diseases and Global Health, Department of Medicine, University of California, San Francisco, CA, USA.
Som S ChatterjeeDivision of HIV/AIDS, Infectious Diseases and Global Health, Department of Medicine, University of California, San Francisco, CA, USA.
University of California, San Francisco · USUniversidade Nova de Lisboa · PTUniversity of British Columbia · CA

Funding

Novel Mechanisms of Beta-lactam Resistance in Staph AureusR01AI100291 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CHATTERJEE, SOM, HENRY CHAMBERS, HENRY F · 2013 to 2023
$5.1M
NIAID NIH HHS R01 AI100291
6 · The paper itself

Abstract

Background: PBP4 is typically considered unimportant for conferring high-level β-lactam resistance in Staphylococcus aureus. Mutations in PBP4 have been associated with β-lactam non-susceptibility among natural strains of S. aureus. We have previously shown that PBP4 can mediate high-level β-lactam resistance in laboratory-generated strains passaged in β-lactam antibiotics. Mutations in the pbp4 promoter that up-regulate its expression and missense mutations that surround PBP4's active site were detected in high frequencies among passaged strains, suggesting PBP4 plays a key role in resistance. How these mutations participate in PBP4's ability to provide high-level β-lactam resistance is unknown. Objectives: To determine whether enzymatic activity of PBP4 is required for high-level β-lactam resistance and to investigate how the pbp4-associated mutations provide β-lactam resistance. Methods: The catalytic activity of PBP4 was disabled through introduction of a serine to alanine point mutation in its active site (Ser-75→Ala) in a representative and well-studied passaged strain, CRB. pbp4 promoter and missense mutations detected in CRB were reconstituted in a WT strain individually and in combination. β-Lactam resistance of the resultant strains was evaluated by population analysis. Bacterial peptidoglycan composition of the pbp4 mutants was evaluated with and without antibiotic treatment using LC. Results: PBP4 inactivation imparted complete β-lactam susceptibility of CRB. Reconstitution of PBP4 missense mutations alone did not impart β-lactam resistance, but did so in synergism with pbp4 promoter mutation. A similar synergistic interaction of pbp4 mutations was observed in enhanced peptidoglycan cross-linking upon antibiotic treatment. Conclusions: PBP4's activity and overexpression both contribute to high-level β-lactam resistance.

Indexed as

beta-Lactam ResistanceGene Expressionbeta-LactamsChromatography, LiquidHydrolysisMutation, MissensePenicillin-Binding ProteinsPeptidoglycanPoint MutationSerial PassageStaphylococcus aureusbeta-LactamsPenicillin-Binding ProteinsPeptidoglycan

Identifiers

PMID29360990
PMCPMC5909641
OpenAlexW2789535952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.